Search DNABW
Ginkgo Bioworks Holdings, Inc.
NYSE · CIK 1830214
Last close0.01
Daily changen/a
10 Years gain+0.00%
Dividends TTM0
Dividend yieldn/a
Fundamental Analysis
DNABW · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
35.3Momentum
80.5Acceleration
88.3Confidence
85.0Annual Revenue7
Quarterly Revenue18
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency7.7 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.1 / 5
Signals
Operating leverageOperating margin improved by 6.0952 percentage points.
ROIC expansionROIC improved by 94.6748 percentage points.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 6.8237 percentage points.
Key Metrics
Revenue Growth TTM-46.89%OK
Revenue CAGR 3Y-29.11%OK
Gross Margin91.33%OK
Operating Margin-236.48%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-66.79%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $170.16M | $170.16M | -$315.28M | -$171.06M | -$178.72M | 100% | -185.29% | -105.04% | -207.16% | 55.46M |
| 2025 FY Dec 31, 2024 | $227.04M | $227.04M | -$559.76M | -$319.59M | -$382.13M | 100% | -246.54% | -168.31% | -287.55% | 51.89M |
| 2025 FY Dec 31, 2023 | $251.46M | $251.46M | -$864.41M | -$295.50M | -$336.30M | 100% | -343.76% | -133.74% | -238.12% | 48.61M |
| 2024 FY Dec 31, 2022 | $477.71M | $477.71M | -$2.21B | -$252.20M | -$304.47M | 100% | -462.41% | -63.74% | -928.61% | 42M |
| 2023 FY Dec 31, 2021 | $313.84M | $313.84M | -$1.83B | -$253.82M | -$310.34M | 100% | -582.62% | -98.89% | -8,039.23% | 1.36B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $117.60M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-054298, 0001628280-25-050193 |
| Revenue Growth TTM | -46.89% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-054298, 0001628280-25-050193 |
| Revenue CAGR 3Y | -29.11% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012346 |
| Revenue CAGR 5Y | 17.29% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-012346 |
| Gross Profit CAGR 3Y | -29.11% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012346 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-054298, 0001628280-25-050193 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 91.33% | Gross Profit / Revenue | OK | 0001628280-26-054298, 0001628280-25-050193 |
| Operating Margin | -236.48% | Operating Income / Revenue | OK | 0001628280-26-054298, 0001628280-25-050193 |
| ROIC | -66.79% | NOPAT / Average Invested Capital | OK | 0001628280-26-054298, 0001628280-25-050193 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-054298 |
| Current Ratio | 4.57x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.85 | Revenue / Diluted Shares | OK | 0001628280-26-054298, 0001628280-25-050193 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |